<code id='93CD3AB70F'></code><style id='93CD3AB70F'></style>
    • <acronym id='93CD3AB70F'></acronym>
      <center id='93CD3AB70F'><center id='93CD3AB70F'><tfoot id='93CD3AB70F'></tfoot></center><abbr id='93CD3AB70F'><dir id='93CD3AB70F'><tfoot id='93CD3AB70F'></tfoot><noframes id='93CD3AB70F'>

    • <optgroup id='93CD3AB70F'><strike id='93CD3AB70F'><sup id='93CD3AB70F'></sup></strike><code id='93CD3AB70F'></code></optgroup>
        1. <b id='93CD3AB70F'><label id='93CD3AB70F'><select id='93CD3AB70F'><dt id='93CD3AB70F'><span id='93CD3AB70F'></span></dt></select></label></b><u id='93CD3AB70F'></u>
          <i id='93CD3AB70F'><strike id='93CD3AB70F'><tt id='93CD3AB70F'><pre id='93CD3AB70F'></pre></tt></strike></i>

          Home / comprehensive / leisure time

          leisure time


          leisure time

          author:knowledge    Page View:284
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In